Skip to main content

What the FDA labels say about taking them together

Carbamazepine and ixazomib

Ixazomib's FDA label of August 11, 2026 names carbamazepine in its drug interactions section; the carbamazepine labels PlainMeds reads (3) do not name ixazomib. The ixazomib label: “Avoid concomitant administration of NINLARO with strong CYP3A inducers.”

Check it at the source: the carbamazepine FDA label on DailyMed (effective August 20, 2026, Novartis Pharmaceuticals Corporation); the ixazomib FDA label on DailyMed (effective August 11, 2026, Takeda Pharmaceuticals America, Inc.).

What does the carbamazepine label say about ixazomib?

Carbamazepine's label (effective August 20, 2026) and its 2 other brand-application labels do not name ixazomib in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Tegretol), Novartis Pharmaceuticals Corporation, effective August 20, 2026 (SPL set 8d409411-aa9f-4f3a-a52c-fbcb0c3ec053), via openFDA; the full label on DailyMed

What does the ixazomib label say about carbamazepine?

Ixazomib label, drug interactions

Avoid concomitant administration of NINLARO with strong CYP3A inducers (such as rifampin, phenytoin, carbamazepine, and St. John's Wort) [see Clinical Pharmacology (12.3) ].

Source: FDA drug label (NINLARO), Takeda Pharmaceuticals America, Inc., effective August 11, 2026 (SPL set 038f2461-834b-4488-9ebd-863c83eef5a7), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

42Carbamazepine generic labelers
0Ixazomib generic labelers
CarbamazepineIxazomib
Labeled forBipolar disorder, Seizures and epilepsyLeukemia, lymphoma and myeloma
Boxed warningYesNo
Pharmacy cost (NADAC)$0.119 per tablet 200 mg tabletn/a
Shortage nowA presentation being discontinuedNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?